"UCB will pay $2bn in upfront cash for Candid Therapeutics, with up to $200m in additional milestone payments tied to development and regulatory progress."
"Candid's lead asset is cizutamig, a bispecific antibody designed to bridge a T-cell and a plasma cell, instructing the T-cell to destroy the plasma cell."
"The 2026 thesis is that the same engine can be repurposed to deplete the autoreactive B-cells and plasma cells driving autoimmune diseases such as lupus and myasthenia gravis."
UCB is purchasing Candid Therapeutics for $2bn upfront, with potential additional payments of $200m. Candid's lead asset, cizutamig, is a bispecific antibody targeting T-cells and plasma cells. This acquisition follows UCB's earlier licensing of a similar therapeutic mechanism. The aim is to leverage T-cell engagers to treat autoimmune diseases by depleting autoreactive B-cells. The deal is expected to close by mid-2023, pending antitrust clearance, and UCB maintains its financial guidance for 2026.
Read at TNW | Health-Tech
Unable to calculate read time
Collection
[
|
...
]